Announcements Trials

Browse Landscape

Phase

Status

Sponsor Class

Study Type

Interventional 1

Sponsor

Conditions

Prostatic Neoplasms 19 Neoplasms 5 Unspecified Adult Solid Tumor, Protocol Specific 2 Glioma 2 Glioblastoma 2 Brain Neoplasms 2 Thromboembolism 1 Solid Tumors 1 Oligodendroglioma 1 Neuroblastoma 1 Lymphoma, Follicular 1 Leukemia, Myeloid, Chronic-Phase 1 Granulosa Cell Tumor 1 Castration-resistant Prostate Cancer 1 Breast Neoplasms 1 Astrocytoma 1 Advanced Cancer 1

Interventions

Surveys and Questionnaires 7 Standard of Care 5 Sirolimus 5 Bevacizumab 5 temsirolimus 4 Interviews as Topic 4 Paclitaxel 3 olaparib 2 Vorinostat 2 Olanzapine 2 Magnetic Resonance Spectroscopy 2 Gemcitabine 2 Everolimus 2 Erlotinib Hydrochloride 2 Dasatinib 2 Cetuximab 2 zaleplon 1 vistusertib 1 tilsotolimod 1 pazopanib 1 olanzapine-fluoxetine combination 1 nimotuzumab 1 liposomal doxorubicin 1 capivasertib 1 apatinib 1 Videotape Recording 1 Vemurafenib 1 Valproic Acid 1 Trastuzumab 1 Topotecan 1

Date Range

30 days 90 days 1 year All

Options

Has results Has announcements

Clinical Trials

1 trials

Recent Start date Enrollment

OTHER × Advanced Cancer × Ketoconazole × Clear all

NCT00708591 2014-01-17

Study of Rapamycin Plus Ketoconazole in Advanced Cancers

University of Chicago

Phase 1 Completed

Advanced Cancer

Data powered by HemOnc (CC BY 4.0) Colophon ⚡